文献速递中医内科中药与中成药合理使用中医康复

中药治疗慢性阻塞性肺疾病急性加重风险窗口的多中心随机对照试验

Efficacy and safety of Chinese medicine in treating risk window of AECOPD: A multicenter randomized controlled trial.
PubMed 文献 · Phytomedicine · 2025-06-06

本研究为多中心随机双盲安慰剂对照试验,纳入336例AECOPD风险窗口患者,在常规治疗基础上加用中医辨证中药颗粒剂或安慰剂,疗程8周、随访26周。结果显示中药可显著降低急性加重风险、延长首次加重时间、改善CAT评分及肺功能等,且安全性良好。

要点

  • 中药辨证治疗可降低AECOPD风险窗口患者8周和26周的急性加重风险。
  • 中药组首次急性加重时间较对照组延长约31.5天,CAT评分显著改善。
  • 中药组在mMRC、FEV1、FVC及症状评分方面均优于对照组。

核心结论

  • 中药辨证治疗AECOPD风险窗口患者可显著减少急性加重发生、延长首次加重时间、缓解临床症状并改善生活质量,且安全性良好。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照平行试验,纳入336例合格受试者,两组均以常规治疗为基础。
  • 试验组给予基于中医辨证的中药颗粒剂,对照组给予中药颗粒剂安慰剂,干预8周,随访26周。

主要发现

  • 8周时试验组急性加重风险显著降低,RR为0.375(95%CI:0.150至0.935;p=0.027),CAT评分平均差异为-2.476分(95%CI:-3.281至-1.671;p<0.001)。
  • 26周时试验组急性加重风险仍显著低于对照组,RR为0.519(95%CI:0.282至0.953;p=0.030)。
  • 试验组首次急性加重时间为(97.63±35.90)天,对照组为(66.11±25.25)天,平均差异为31.517天(95%CI:14.720至48.314;p<0.001)。
  • 风险窗口及随访期间两组急性加重再住院率相似;随访26周后试验组CAT评分组间降低2.046分(p<0.001)。
  • 整个研究期间试验组mMRC评分、FEV1和FVC值均显著改善(均p<0.05),咳嗽、咳痰、乏力等症状评分显著降低(p<0.05)。

临床怎么用

  • 在常规治疗基础上,可对AECOPD风险窗口患者进行中医辨证并给予中药颗粒剂治疗,以降低急性加重风险。
  • 治疗8周即可观察到急性加重风险和CAT评分的改善,26周随访仍显示获益。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) significantly accelerate disease progression and substantially increase mortality risk. The risk window of AECOPD (AECOPDRW) represents a time between acute exacerbation and recovery to a stable stage. Chinese medicine (CM) has shown significant therapeutic efficacy in COPD but CM treatment for AECOPDRW has not been validated by high-quality clinical studies. PURPOSE: To assess the clinical effect of CM syndrome differentiation treatment for patients with AECOPDRW. STUDY DESIGN: A multicenter, randomized, double-blind, placebo-controlled parallel trial. METHODS: 336 eligible participants were included to the study. Both groups were based on the conventional treatment as the baseline therapy. The experimental group was administered Chinese herbal medicine granules based on CM syndrome differentiation, whereas the control group received a placebo in the form of Chinese herbal medicine granules. The intervention course lasted for 8-week, while the follow-up for 26-week. Primary outcomes were incidences of acute exacerbation and COPD Assessment Test (CAT) scores recorded during AECOPDRW. Secondary outcomes were the timing of the first acute exacerbation, incidence of exacerbations, acute exacerbation readmission rate, severity of exacerbation, and CAT scores during follow-up, pulmonary function, mMRC scale, clinical symptom scale, and the quality of life assessment tools. RESULTS: At 8-week, the risk of acute exacerbations and CAT score were significantly reduced in the experimental group between-group analysis with a risk ratio (RR) of 0.375(95 % confidence interval [CI]: 0.150 to 0.935; p = 0.027), and a mean difference (MD) of -2.476 score (95 % CI: -3.281 to -1.671; p < 0.001). At 26-week, experimental group showed statistically lower risk of acute exacerbation between-group analysis (RR: 0.519; 95 % CI: 0.282 to 0.953; p = 0.030). The first exacerbation time in the experimental group (97.63 ± 35.90) was statistically longer than in the control group (66.11 ± 25.25) (MD: 31.517 (95 % CI: 14.720 to 48.314; p < 0.001). The rates of acute exacerbation readmission were similar for both the groups during the risk window and follow-up period. After 26 weeks of follow-up, experimental group CAT score was reduced by 2.046 between-group analysis (p < 0.001). Furthermore, during the whole study, the experimental group showed significantly reduced in mMRC score, as well as FEV1 and FVC values (all p < 0.05). During study period, the experimental group had a significant reduce in clinical symptom scores, including cough, expectoration, and fatigue, than the control group (p < 0.05). Regarding to SGRQ, mCOPD-PRO and mESQ-COPD, our results demonstrated that CM had better advantages in many aspects. CONCLUSION: Treatment of AECOPDRW with CM showed high efficacy and safety in significantly reducing further incidences of acute exacerbation, prolonging the interval to the initial acute exacerbation, alleviating the clinical symptoms, and improving the quality of life.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Li J, Zhang H, Ruan H, et al. Efficacy and safety of Chinese medicine in treating risk window of AECOPD: A multicenter randomized controlled trial. Phytomedicine. 2025. PMID: 40513323. doi:10.1016/j.phymed.2025.156903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。